Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry.

Thomas A, Walpurgis K, Krug O, Schänzer W, Thevis M

Journal of chromatography. A28 Jul 2012Cited by 42 (Europe PMC)

PMID22901302DOI10.1016/j.chroma.2012.07.022PepBankPUB-22901302

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of GHRP-2 aloneEx vivo tissueOther
In urine, a nanoUHPLC high-resolution MS/MS screening assay for 11 prohibited peptides, including GHRP‑2, reached limits of detection of 2-10 pg/mL.
In plain wordsIn lab tests on urine, a screening method detected GHRP‑2 at levels as low as 2-10 pg/mL.
Peptide
GHRP-2
Outcome
Not applicableLimit of detection in urine
Study
n: not reported in source
Urine
Outcome group
Analytical methods and detection · Pharmacology
Measurements
limit of detection
2 to 10 pg/mL
11-peptide assay
Source sentences
Summary
limits of detection (2-10 pg/mL)
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, a screening assay was developed comprising 11 prohibited peptides (<1.5 kDa) that are sufficiently purified from urine using weak cation exchange with subsequent determination of all substances by means of nanoUHPLC separation coupled to high resolution tandem mass spectrometry.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2290130201
02LabNot a test of Hexarelin aloneEx vivo tissueOther
In urine, a nanoUHPLC high-resolution MS/MS screening assay for 11 prohibited peptides, including hexarelin, reached limits of detection of 2-10 pg/mL.
In plain wordsIn lab tests on urine, a screening method detected hexarelin at levels as low as 2-10 pg/mL.
Peptide
Hexarelin
Outcome
Not applicableLimit of detection in urine
Study
n: not reported in source
Urine
Outcome group
Analytical methods and detection · Pharmacology
Measurements
limit of detection
2 to 10 pg/mL
11-peptide assay
Source sentences
Summary
limits of detection (2-10 pg/mL)
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, a screening assay was developed comprising 11 prohibited peptides (<1.5 kDa) that are sufficiently purified from urine using weak cation exchange with subsequent determination of all substances by means of nanoUHPLC separation coupled to high resolution tandem mass spectrometry.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-2290130202
03LabNot a test of GHRP-2 aloneEx vivo tissueOther
In urine, the 11-peptide screening assay, which covers GHRP‑2, had a recovery of 45-95%.
In plain wordsIn lab tests on urine, the screening method recovered 45-95% of the peptides, GHRP‑2 among them.
Peptide
GHRP-2
Outcome
Not applicableExtraction recovery from urine
Study
n: not reported in source
Urine
Outcome group
Analytical methods and detection · Pharmacology
Measurements
recovery
45 to 95%
11-peptide assay
Source sentences
Summary
recovery (45-95%)
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, a screening assay was developed comprising 11 prohibited peptides (<1.5 kDa) that are sufficiently purified from urine using weak cation exchange with subsequent determination of all substances by means of nanoUHPLC separation coupled to high resolution tandem mass spectrometry.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2290130203
04LabNot a test of Hexarelin aloneEx vivo tissueOther
In urine, the 11-peptide screening assay, which covers hexarelin, had a recovery of 45-95%.
In plain wordsIn lab tests on urine, the screening method recovered 45-95% of the peptides, hexarelin among them.
Peptide
Hexarelin
Outcome
Not applicableExtraction recovery from urine
Study
n: not reported in source
Urine
Outcome group
Analytical methods and detection · Pharmacology
Measurements
recovery
45 to 95%
11-peptide assay
Source sentences
Summary
recovery (45-95%)
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, a screening assay was developed comprising 11 prohibited peptides (<1.5 kDa) that are sufficiently purified from urine using weak cation exchange with subsequent determination of all substances by means of nanoUHPLC separation coupled to high resolution tandem mass spectrometry.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-2290130204
05LabNot a test of GHRP-2 aloneEx vivo tissueOther
In urine, the 11-peptide screening assay, which covers GHRP‑2, had a precision below 20% at 100 pg/mL.
In plain wordsIn lab tests on urine, the screening method for GHRP‑2 and other peptides had a precision below 20% at 100 pg/mL.
Peptide
GHRP-2
Outcome
Not applicableAssay precision in urine
Study
n: not reported in source
Urine
Outcome group
Analytical methods and detection · Pharmacology
Measurements
precision
< 20%
100 pg/mL
Source sentences
Summary
precision (<20% at 100 pg/mL)
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, a screening assay was developed comprising 11 prohibited peptides (<1.5 kDa) that are sufficiently purified from urine using weak cation exchange with subsequent determination of all substances by means of nanoUHPLC separation coupled to high resolution tandem mass spectrometry.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2290130205
06LabNot a test of Hexarelin aloneEx vivo tissueOther
In urine, the 11-peptide screening assay, which covers hexarelin, had a precision below 20% at 100 pg/mL.
In plain wordsIn lab tests on urine, the screening method for hexarelin and other peptides had a precision below 20% at 100 pg/mL.
Peptide
Hexarelin
Outcome
Not applicableAssay precision in urine
Study
n: not reported in source
Urine
Outcome group
Analytical methods and detection · Pharmacology
Measurements
precision
< 20%
100 pg/mL
Source sentences
Summary
precision (<20% at 100 pg/mL)
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, a screening assay was developed comprising 11 prohibited peptides (<1.5 kDa) that are sufficiently purified from urine using weak cation exchange with subsequent determination of all substances by means of nanoUHPLC separation coupled to high resolution tandem mass spectrometry.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-2290130206
07LabNot a test of GHRP-2 aloneEx vivo tissueOther
In urine, the 11-peptide screening assay, which covers GHRP‑2, was linear from 0 to 500 pg/mL.
In plain wordsIn lab tests on urine, the screening method for GHRP‑2 and other peptides worked across 0-500 pg/mL.
Peptide
GHRP-2
Outcome
Not applicableAssay linearity range in urine
Study
n: not reported in source
Urine
Outcome group
Analytical methods and detection · Pharmacology
Measurements
linearity range
0 to 500 pg/mL
11-peptide assay
Source sentences
Summary
linearity (0-500 pg/mL)
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, a screening assay was developed comprising 11 prohibited peptides (<1.5 kDa) that are sufficiently purified from urine using weak cation exchange with subsequent determination of all substances by means of nanoUHPLC separation coupled to high resolution tandem mass spectrometry.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2290130207
08LabNot a test of Hexarelin aloneEx vivo tissueOther
In urine, the 11-peptide screening assay, which covers hexarelin, was linear from 0 to 500 pg/mL.
In plain wordsIn lab tests on urine, the screening method for hexarelin and other peptides worked across 0-500 pg/mL.
Peptide
Hexarelin
Outcome
Not applicableAssay linearity range in urine
Study
n: not reported in source
Urine
Outcome group
Analytical methods and detection · Pharmacology
Measurements
linearity range
0 to 500 pg/mL
11-peptide assay
Source sentences
Summary
linearity (0-500 pg/mL)
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, a screening assay was developed comprising 11 prohibited peptides (<1.5 kDa) that are sufficiently purified from urine using weak cation exchange with subsequent determination of all substances by means of nanoUHPLC separation coupled to high resolution tandem mass spectrometry.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-2290130208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 5 to 19Current
28 Oct 2026, 02:02 UTC
The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.
Study results updated
Versions 3 to 4
13 Oct 2026, 16:31 UTC
The same notice was added 2 times, first on 13 Oct 2026, 16:31 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 2
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry.

Summary

Results from this study8

Studies that did not test the peptide alone8

Version history

Subjects

Publication types

MeSH terms